Journal article
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
S O'Brien, JA Jones, SE Coutre, AR Mato, P Hillmen, C Tam, A Österborg, T Siddiqi, MJ Thirman, RR Furman, O Ilhan, MJ Keating, TG Call, JR Brown, M Stevens-Brogan, Y Li, F Clow, DF James, AD Chu, M Hallek Show all
Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2016
Abstract
Background The TP53 gene, encoding tumour suppressor protein p53, is located on the short arm of chromosome 17 (17p). Patients with 17p deletion (del17p) chronic lymphocytic leukaemia have poor responses and survival after chemoimmunotherapy. We assessed the activity and safety of ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase, in relapsed or refractory patients with del17p chronic lymphocytic leukaemia or small lymphocytic lymphoma. Methods We did a multicentre, international, open-label, single-arm study at 40 sites in the USA, Canada, Europe, Australia, and New Zealand. Patients (age ≥18 years) with previously treated del17p chronic lymphocytic leukaemia or small lympho..
View full abstractGrants
Funding Acknowledgements
We thank the patients who participated in the study, their supporters, and the investigators and clinical research staff from the study centres. This manuscript was developed with editorial support from Luana Atherly-Henderson from Nexus Global Group Science LLC and funded by Pharmacyclics LLC, an AbbVie Company.